Negotiate with time

What can actually slow aging?

Lifestyle changes, targeted therapeutics, and emerging technologies that can measurably slow, stabilize, or partially reverse aspects of biological aging — rated by evidence quality.

Lifestyle

Behavioral changes with strong or promising evidence for slowing biological aging.

Exercise (Aerobic + Resistance)

STRONG

Regular physical activity is the most consistently validated intervention for slowing epigenetic aging acceleration.

Mechanism

Reduces systemic inflammation, improves mitochondrial function, modulates DNA methylation patterns at aging-associated CpG sites, improves insulin sensitivity and cardiovascular function.

Clock responsiveness

Multiple RCTs show reduced epigenetic age acceleration. DunedinPACE responds to sustained exercise programs. Phenotypic clocks improve via biomarker normalization.

Practical notes

150+ minutes moderate aerobic activity per week plus 2+ resistance sessions. Effects are dose-dependent but diminishing returns at extreme volumes. Consistency matters more than intensity.

What we don't know

Optimal exercise dose for maximum clock response. Whether exercise-driven clock reversal reflects true biological rejuvenation or biomarker normalization. Long-term durability of effects after cessation.

Key findings

  • •Epigenetic age deceleration in multiple RCTs
  • •DunedinPACE slowing with sustained programs
  • •Phenotypic biomarker improvement within weeks
  • •Effects persist with continued adherence

Diet Quality & Caloric Management

STRONG

Mediterranean-style diets and moderate caloric restriction show consistent epigenetic age benefits across multiple studies.

Mechanism

Anti-inflammatory nutrient profiles reduce NF-kB signaling, improve metabolic markers, modulate glycan profiles (reducing pro-inflammatory glycosylation), and affect DNA methylation at aging-associated sites.

Clock responsiveness

Mediterranean diet shown to slow DunedinPACE in CALERIE trial context. GlycanAge highly responsive to dietary changes. Phenotypic clocks improve via metabolic biomarker optimization.

Practical notes

Emphasize whole foods, vegetables, healthy fats, lean protein. Avoid ultra-processed foods. Moderate caloric restriction (10-15%) without malnutrition. Time-restricted eating shows early promise.

What we don't know

Whether specific dietary patterns are optimal for specific clock types. Long-term sustainability of caloric restriction benefits. Individual genetic variation in dietary response.

Key findings

  • •CALERIE trial: caloric restriction slowed DunedinPACE
  • •Mediterranean diet associated with lower epigenetic age acceleration
  • •GlycanAge responds to dietary interventions within months
  • •Anti-inflammatory diets improve phenotypic biomarkers

Sleep Optimization

STRONG

Consistent, quality sleep is associated with slower biological aging across multiple clock types.

Mechanism

Sleep supports DNA repair, immune function, hormonal regulation, and inflammatory resolution. Chronic sleep disruption accelerates epigenetic aging and shifts immune/inflammatory profiles.

Clock responsiveness

Sleep deprivation accelerates epigenetic clocks in observational studies. Inflammatory markers (reflected in glycomic and immune clocks) worsen with poor sleep. Phenotypic biomarkers improve with sleep restoration.

Practical notes

7-9 hours for most adults. Consistent timing matters. Address sleep apnea and other disorders. Blue light management, temperature optimization, and stress reduction support sleep quality.

What we don't know

Whether sleep improvement can reverse accumulated epigenetic damage. Optimal sleep duration for different ages. How much clock sensitivity to sleep disruption is transient vs lasting.

Key findings

  • •Sleep disruption associated with accelerated epigenetic aging
  • •Inflammatory markers worsen with chronic poor sleep
  • •Clock sensitivity to short-term sleep loss may confound reversal claims
  • •Sleep quality correlates with biological age across populations

Chronic Stress Reduction

PROMISING

Meditation, mindfulness, and psychosocial stress reduction show evidence of slowing biological aging.

Mechanism

Reduces cortisol and inflammatory cytokines, improves telomere maintenance, modulates immune cell profiles, and may influence DNA methylation at stress-responsive CpG sites.

Clock responsiveness

Some intervention studies show epigenetic age reduction with meditation programs. Immune/inflammatory clocks may respond to stress reduction. Telomere maintenance improved in some RCTs.

Practical notes

Regular meditation or mindfulness practice (15-30 min daily). Social connection and purpose also matter. Chronic psychological stress is a modifiable accelerator of biological aging.

What we don't know

Dose-response relationship for different stress-reduction practices. Which clock types are most responsive. Whether effects are independent of improved sleep and exercise that often co-occur.

Key findings

  • •Some RCTs show epigenetic age reduction with meditation
  • •Telomere lengthening observed in stress-reduction interventions
  • •Inflammatory markers improve with chronic stress management
  • •Effect sizes are modest and studies are often small

Smoking Cessation

STRONG

Quitting smoking is one of the most impactful single interventions for reducing epigenetic age acceleration.

Mechanism

Smoking directly accelerates DNA methylation aging, increases GrimAge components (DNAm surrogates of smoking-related proteins), drives inflammation and glycan profile deterioration.

Clock responsiveness

GrimAge was literally built to capture smoking-driven mortality risk. Smoking cessation partially reverses DNAm changes at smoking-associated CpGs. Inflammatory and glycomic markers improve within months.

Practical notes

Complete cessation preferred. Partial reversal of epigenetic damage occurs over years. Benefits begin within weeks for inflammatory markers.

What we don't know

How completely epigenetic smoking signatures reverse over time. Whether long-term ex-smokers fully normalize their biological age clocks. Interaction with other interventions.

Key findings

  • •GrimAge directly incorporates DNAm smoking surrogates
  • •Cessation partially reverses smoking-associated methylation changes
  • •Inflammatory markers improve rapidly after quitting
  • •Residual epigenetic signatures may persist for years

Targeted Therapeutics

Drugs and compounds being studied as potential geroprotectors. Promising but not yet proven for healthy humans.

Metformin

PROMISING

The diabetes drug being studied in the TAME trial as a potential geroprotector. Epidemiological data suggest reduced age-related disease in diabetic users.

Mechanism

Activates AMPK, inhibits mTOR, reduces inflammation, improves insulin sensitivity, may modulate DNA methylation patterns through metabolic pathway effects.

Clock responsiveness

Limited direct clock data in healthy humans. The TAME (Targeting Aging with Metformin) trial will be the first large RCT measuring aging endpoints. Some observational data suggest lower epigenetic age in users.

Practical notes

Prescription medication. Typically 500-1500mg daily. GI side effects common initially. Off-label longevity use is widespread but not evidence-based for non-diabetics yet.

What we don't know

Whether metformin benefits healthy non-diabetics. TAME trial results pending. Whether it actually slows biological aging clocks or just improves metabolic markers. Interaction with exercise benefits.

Key findings

  • •TAME trial (ongoing): first geroprotector RCT with aging endpoints
  • •Epidemiological: diabetic metformin users may have lower mortality than non-diabetic controls
  • •May blunt some exercise benefits (concurrent use concerns)
  • •Direct epigenetic clock evidence in healthy humans is limited

Rapamycin / mTOR Inhibitors

PROMISING

The most robust lifespan-extending drug in animal models. Human longevity data is early but growing.

Mechanism

Inhibits mTOR (mechanistic target of rapamycin), enhancing autophagy, reducing senescent cell burden, modulating immune function, and improving proteostasis.

Clock responsiveness

Animal studies show epigenetic age reversal. Early human studies (PEARL, others) examining intermittent low-dose protocols. No large RCT data on human biological age clocks yet.

Practical notes

Prescription immunosuppressant with significant side-effect profile at standard doses. Longevity protocols use intermittent low-dose (e.g., weekly) to minimize immunosuppression. Not FDA-approved for aging.

What we don't know

Optimal dosing for longevity vs immunosuppression. Long-term safety of intermittent protocols. Whether animal lifespan results translate to humans. Direct effects on human biological age clocks.

Key findings

  • •Extends lifespan across multiple animal species
  • •Epigenetic age reversal in animal studies
  • •Early human trials exploring intermittent low-dose protocols
  • •Significant safety considerations limit widespread use

NAD+ Precursors (NMN, NR)

EMERGING

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) aim to boost cellular NAD+ levels, which decline with age.

Mechanism

Supplement NAD+ biosynthesis pathway. NAD+ is essential for sirtuins, PARP-mediated DNA repair, and mitochondrial function. Age-related NAD+ decline is well-documented.

Clock responsiveness

Limited direct biological age clock data. Some small studies show biomarker improvements. No large RCTs demonstrating clock reversal. Mechanistic plausibility but translation uncertain.

Practical notes

Available as supplements (NMN, NR). Typical doses 250-1000mg daily. Generally well-tolerated. Quality and purity vary widely across brands. Regulatory status varies by country.

What we don't know

Whether raising NAD+ levels actually reverses biological aging clocks. Optimal dose and form (NMN vs NR). Long-term safety data. Whether benefits extend beyond biomarker changes.

Key findings

  • •NAD+ decline with age is well-established
  • •Small human studies show NAD+ level increases
  • •Biological age clock effects not yet demonstrated in RCTs
  • •Mechanistic plausibility strong but clinical translation unclear

Senolytics (Dasatinib + Quercetin, Fisetin)

EMERGING

Drugs that selectively eliminate senescent cells, which accumulate with age and drive inflammation and tissue dysfunction.

Mechanism

Target anti-apoptotic pathways in senescent cells, enabling their clearance. Reduces SASP (senescence-associated secretory phenotype), a major driver of inflammaging and tissue dysfunction.

Clock responsiveness

Animal studies show biological age reversal with senolytic treatment. Human pilot studies (D+Q in idiopathic pulmonary fibrosis, diabetic kidney disease) show promise. No large-scale clock studies yet.

Practical notes

Dasatinib is a prescription cancer drug. Quercetin and fisetin are available as supplements. D+Q protocols typically use intermittent dosing (hit-and-run approach). Safety profile not established for chronic use.

What we don't know

Whether senolytic-driven senescent cell clearance actually reverses biological age clocks in humans. Optimal timing, dosing, and target populations. Long-term effects of periodic senescent cell elimination.

Key findings

  • •Animal studies: biological age reversal and healthspan extension
  • •Human pilot studies show feasibility and some biomarker improvements
  • •Intermittent dosing may be sufficient (hit-and-run)
  • •Large-scale human clock studies not yet completed

Emerging Technologies

Experimental approaches in early research stages. Exciting science but far from clinical use.

Partial Cellular Reprogramming

EMERGING

Using Yamanaka factors (OSKM) to partially reprogram cells back to a more youthful epigenetic state without full de-differentiation.

Mechanism

Transient expression of Oct4, Sox2, Klf4, and c-Myc can reset epigenetic marks associated with aging while preserving cell identity. In mice, partial reprogramming rejuvenates tissues and extends lifespan.

Clock responsiveness

Demonstrates epigenetic age reversal in mouse studies and in vitro human cell models. Altos Labs, Retro Biosciences, and others are pursuing human translation.

Practical notes

Entirely experimental. Not available outside research settings. Major safety concerns including cancer risk (c-Myc is an oncogene). Delivery, dosing, and tissue targeting are unsolved challenges.

What we don't know

Whether partial reprogramming is safe in humans. Optimal factor combination and delivery method. Whether epigenetic age reversal translates to functional rejuvenation. Timeline to human therapies.

Key findings

  • •Mouse studies: tissue rejuvenation and lifespan extension
  • •Epigenetic age reversal demonstrated in vitro
  • •Major biotech investment (Altos Labs, Retro Biosciences)
  • •Safety and delivery remain fundamental challenges

Young Plasma / Parabiosis Factors

EMERGING

Research into factors in young blood that may rejuvenate aged tissues, inspired by parabiosis experiments in mice.

Mechanism

Young blood contains factors (GDF11, oxytocin, others) that may rejuvenate aged tissues. Heterochronic parabiosis in mice shows rejuvenation of muscle, brain, liver. Plasma exchange studies exploring dilution of pro-aging factors.

Clock responsiveness

Animal parabiosis shows epigenetic age changes. Human plasma exchange pilot studies exist. Direct biological age clock data in humans is very limited.

Practical notes

Not available as a validated therapy. Plasma exchange is a medical procedure. Young plasma transfusion (Ambrosia-style) was warned against by FDA. Active research area with no consumer-ready product.

What we don't know

Which specific factors drive rejuvenation. Whether plasma exchange or specific factors are more effective. Safety of repeated plasma manipulation. Human clock response data.

Key findings

  • •Parabiosis experiments: tissue rejuvenation in old mice
  • •Specific factors (GDF11) identified but debated
  • •Plasma dilution may be as important as young factor addition
  • •FDA has warned against unproven young plasma treatments

Hyperbaric Oxygen Therapy (HBOT)

EMERGING

Breathing pure oxygen at elevated pressure. One small trial reported telomere lengthening and senescent cell reduction.

Mechanism

Intermittent hyperoxia may trigger hormetic response, mobilize stem cells, reduce senescent cells, and modulate immune function through oxidative stress signaling.

Clock responsiveness

One small Israeli study (n=35) reported telomere lengthening and senescent cell reduction. Epigenetic clock data is very limited. Results not independently replicated at scale.

Practical notes

Requires specialized chambers. Expensive ($100-250 per session, 60+ sessions in study protocol). Established medical use for wound healing, decompression sickness. Longevity claims far ahead of evidence.

What we don't know

Whether the small trial results replicate. Optimal protocol (pressure, duration, frequency). Whether telomere changes translate to meaningful biological age reversal. Long-term safety of repeated protocols.

Key findings

  • •One small trial (n=35): telomere lengthening, senescent cell reduction
  • •Results not independently replicated
  • •Established medical therapy repurposed for longevity claims
  • •Cost and access are significant barriers

Important: This information is for educational purposes only. No intervention listed here is medical advice. Consult a healthcare provider before starting any new supplement, medication, or therapy. Evidence tiers reflect the current state of published research, not clinical recommendations.